Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BIRD, H. A.
Right arrow Articles by WRIGHT, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BIRD, H. A.
Right arrow Articles by WRIGHT, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1981 British Society for Rheumatology

research-article

ENTERIC-COATED ASPIRIN IN RHEUMATOID ARTHRITIS

H. A. BIRD, V. RHIND, P. LEATHAM, A. SAUNDERS and V. WRIGHT

Clinical Pharmacology Unit, Royal Bath Hospital Harrogate, North Yorkshire
Rheumatism Research Unit, University Department of Medicine, General Infirmary Leeds

Correspondence to: Requests for reprints to Dr. H. A. Bird, Clinical Pharmacology Unit (Rheumatism Research), Royal Bath Hospital, Cornwall Road, Harrogate HG1 2PS

Sixty patients with active rheumatoid arthritis (mean ESR = 51 mm/h) were treated for six months with D-penicillamine (15 patients), sodium aurothiomalate (15 patients), hydroxychloroquine (15 patients) or enteric-coated aspirin (15 patients). The three groups receiving specific anti-rheumatoid therapy were also allowed enteric-coated aspirin in the dose of their choice as the only "back-up" drug; the group treated with aspirin alone was encouraged to take the maximum tolerated dose.

The mean duration of treatment tolerated by patients receiving aspirin alone was 12.3 weeks. Only four patients completed a 24-week treatment period and no improvement was seen in acute-phase reactants. Those patients receiving an anti-rheumatoid drug showed serial improvement in ESR as the dose of aspirin required fell. Plasma salicylate concentrations correlated well with aspirin dosage.

Even as an enteric-coated formulation, aspirin alone is not the treatment of choice for active rheumatoid disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.